Compare RFIL & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RFIL | NRXP |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 73.7M |
| IPO Year | N/A | N/A |
| Metric | RFIL | NRXP |
|---|---|---|
| Price | $5.98 | $2.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $9.25 | ★ $31.60 |
| AVG Volume (30 Days) | 70.6K | ★ 443.6K |
| Earning Date | 01-15-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $76,353,000.00 | $242,000.00 |
| Revenue This Year | $21.53 | N/A |
| Revenue Next Year | $4.92 | $643.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.60 | N/A |
| 52 Week Low | $3.39 | $1.15 |
| 52 Week High | $9.56 | $6.01 |
| Indicator | RFIL | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 33.67 | 41.32 |
| Support Level | $5.86 | $1.99 |
| Resistance Level | $6.44 | $2.51 |
| Average True Range (ATR) | 0.43 | 0.21 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 25.75 | 32.93 |
RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company operates through two segments: RF Connector and Cable Assembly, which consists of the Connector and Cable Assembly Division, and Custom Cabling Manufacturing and Assembly, which consists of its subsidiaries. Connector segment designs, manufactures, markets and distributes a broad range of RF connector, adapter, coupler, divider, and cable products etc. The Custom Cabling segment custom copper and fiber cable assemblies etc. The company operates in Canada, Italy, China, USA, UK.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.